Acumen Pharmaceuticals (ABOS)
(Delayed Data from NSDQ)
$3.00 USD
+0.05 (1.69%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $3.00 0.00 (0.00%) 6:12 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABOS 3.00 +0.05(1.69%)
Will ABOS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ABOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABOS
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
ABOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
Other News for ABOS
Acumen presents data on pTau217 assay to screen for Phase 2 ALTITUDE-AD trial
Acumen presents data on pTau217 assay to screen for Phase 2 ALTITUDE-AD trial
Acumen to deliver late-breaking presentation on ACU193 at CTAD conference
Acumen to deliver late-breaking presentation on ACU193 at CTAD conference
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV) and Acumen Pharmaceuticals (ABOS)